Kim Munk

Association between endogenous complement inhibitor and myocardial salvage in patients with myocardial infarction

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Many pathogenic processes and diseases are the result of an erroneous activation of the complement cascade and a number of inhibitors of complement have thus been examined for anti-inflammatory actions. It was recently demonstrated that supraphysiological concentrations of the endogenous complement inhibitor MAp44 (also denoted MAP1) protect against myocardial reperfusion injury. In the present study, we examined the association between outcome after acute myocardial infarction (MI) and the plasma levels of MAp44 and its related proteins MASP-1 and MASP-3 in patients with first-time MI. In addition, we compared plasma levels of MAp44, MASP-1, and MASP-3 in MI patients to levels in a healthy control group.
Original languageEnglish
JournalEuropean Heart Journal: Acute Cardiovascular Care
Pages (from-to)3-9
Number of pages7
Publication statusPublished - 1 Mar 2014

See relations at Aarhus University Citationformats

ID: 70845732